Bio-Rad Laboratories, Inc. BIOB
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 23.48% | 170.46% | -173.21% | 310.59% | -207.58% |
| Total Depreciation and Amortization | 0.24% | 0.49% | -3.76% | -3.85% | 8.87% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -14.29% | -159.28% | 189.56% | -263.47% | 263.32% |
| Change in Net Operating Assets | -18.06% | 182.14% | -166.31% | 348.14% | -232.81% |
| Cash from Operations | -2.33% | -8.70% | -34.45% | 36.39% | 3.78% |
| Capital Expenditure | 2.50% | -6.67% | 34.50% | -44.48% | 30.63% |
| Sale of Property, Plant, and Equipment | -- | -200.00% | -- | -- | -100.00% |
| Cash Acquisitions | -100.00% | -- | -- | 100.00% | 99.17% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -221.29% | 43.60% | -645.69% | 222.11% | -106.47% |
| Cash from Investing | -118.74% | 28.43% | -172.51% | 20.47% | 62.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 50.00% | -100.00% | 50.00% | -- | 100.00% |
| Issuance of Common Stock | -14.29% | 23.53% | -12.82% | 14.71% | -19.05% |
| Repurchase of Common Stock | 83.86% | 33.89% | -11,850.00% | 99.28% | 60.16% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | -- | -- | -- |
| Cash from Financing | 94.20% | 37.27% | -1,433.33% | 106.29% | 61.48% |
| Foreign Exchange rate Adjustments | -111.11% | -8.47% | -- | -100.00% | 106.79% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -627.55% | 142.24% | -117.31% | 405.66% | 117.50% |